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Objectives. Tuscany region (Italy) recorded a rise in the num-
ber of meningococcal disease cases between January 2015 and 
February 2016, (52 cases) compared to 2014 (16 cases). The aim 
of this study was to describe the emergency meningococcal C 
(MenC) vaccination programme in Tuscany and the population’s 
adherence to the activities performed in the Local Health Unit 
(LHU) of Florence. 
Methods. The MenC vaccination programme and the planning of 
the prevention and communication activities were analysed in the 
LHU of Florence. As an indicator of population’s adherence, the 
vaccination coverage (VC) during the emergency campaign was 
investigated and adverse drug reactions (ADR) surveillance was 
reported. 
Results. The communication campaign included a dedicated 
toll-free telephone number, press releases (newspapers, radio, 
television, websites), and informative letters addressed to may-
ors, secondary schools, and sports associations. Citizens aged 
11-20 years were the primary target of the campaign. Due to the 
high incidence of cases among older people, the vaccination was 
extended to subjects over 45 years. The population’s adherence 
to the vaccination campaign was satisfactory: VC reached 47.1% 
for the primary target. The ADR reporting rate (3.1/10,000) on 
meningococcal vaccine in our study confirmed the safety of the 
vaccination.
Conclusions. In 2017, only 10 cases of invasive meningococcal 
diseases (IMD) were reported, suggesting the effectiveness of the 
immunization campaign. Similar VC during emergency MenC 
vaccination programmes have been reached in other Italian 
regions and other EU countries, too. The achievement of greater 
vaccination coverage is restricted by a sentiment of hesitancy 
towards vaccines among the general population.
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Summary
Introduction
Neisseria meningitidis represents a major cause of 
meningitis and septicaemia, and it is also a leading 
cause of morbidity and case fatality rate in all age 
groups worldwide. Meningococcal disease can lead 
to permanent sequelae, such as skin scarring, abnor-
mal bone growth, limb loss and multiple amputations, 
hearing loss, cognitive deficits and visual impair-
ment [1-3]. In Europe, most cases of invasive menin-
gococcal disease (IMD) are caused by serogroups B 
and C, and the annual notification rate was between 
0.55/100,000 population and 1.19/100,000 in the pe-
riod 2004-2014 [4]. In Italy, the incidence of menin-
gococcal disease was 0.27/100,000 in 2014 [5]. 
Italian regions can implement different immuni-
zation policies and Tuscany was one of the first to 
recommend meningococcal  C vaccination  [6]. Since 
2005, Tuscany, a central region of Italy with around 
3,750,000 inhabitants, has offered the meningococ-
cal C conjugate (MenC) vaccine free of charge at the 
regional level to all newborns, in the form of a three-
dose MenC schedule at three, five, and 13 months of 
age and a catch-up dose to the children up to six years 
of age. Since 2008, the MenC vaccine has been of-
fered to all children in a single-dose schedule at 13 
months of age, along with the catch-up strategy. This 
immunization program has proved to be effective in 
preventing IMD among the birth cohorts involved in 
the regional offer. Between 2005 and 2014, the num-
ber of IMD cases decreased drastically and no cases 
occurred among the vaccinated subjects [7]. In addi-
tion, since 2014, a catch-up dose of quadrivalent con-
jugate ACWY vaccine has been offered free of charge 
to adolescents aged between 11 and 18 years who 
were never vaccinated [8]. 
However, an increased number of meningococcal dis-
ease cases was observed in Tuscany between 2015 and 
2016 compared to the previous years. A total of 38 
cases occurred in 2015 (31 serogroup C, 5 serogroup 
B, 1 serogroup W and 1 unknown) and 41 cases in 
2016 (30 serogroup C, 8 serogroup B, 1 serogroup W, 
1 serogroup X and 1 unknown), while only 16 cases 
(9 serogroup B, 3 serogroup Y, 2 serogroup C, 1 sero-
group A and 1 unknown) had occurred in 2014 [9]. In 
most cases, molecular typing identified meningococ-
cal serogroup C clonal complex ST-11: a particularly 
virulent clone of N. meningitidis [10]. 
The unexpected increase in the number of meningo-
coccal disease cases was reported to the surveillance 
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system. This called for an appropriate public health 
intervention, including an emergency immunization 
campaign, which started from April 2015. 
The current study was aimed at describing the emer-
gency meningococcal  C vaccination programme in 
Tuscany and the population’s adherence to the activi-
ties performed in the LHU of Florence – with around 
815,000 inhabitants – between January 2015 and Feb-
ruary 2016. 
Methods
Emergency meningococcal C vaccination 
programme in Tuscany and the planning  
of prevention activities in the LHU  
of Florence
Regional deliberations on the meningococcal C vac-
cination offer were collected for January 2015 - Feb-
ruary 2016, and the whole vaccination programme in 
Tuscany was analysed. 
The planning and communication activities of the 
emergency vaccination programme in the LHU of 
Florence were deeply analysed and described. In our 
analyses, we considered the professionals who were 
involved in the organization and monitoring of the 
vaccination campaign or in administering the vaccine. 
Moreover, we also investigated the settings that were 
selected for the administration of the vaccine.
We also analysed how the need for the vaccine doses 
to be administered to the target population was es-
timated and how often the vaccination demand was 
evaluated to adapt the vaccines supply.
Data collection, reporting,  
and the analysis of communication 
activities and the population’s adherence  
to the emergency campaign
We analysed the communication strategies developed 
to improve population’s adherence. We also evaluated 
how the vaccine was administered and which profes-
sionals were involved in it.
The demand for vaccination, the available slots, and 
the first date available for vaccination were also in-
vestigated.
Immunization coverage was calculated for the age 
groups involved in the vaccination programme among 
the resident population between April 2015 and Feb-
ruary 2016. Immunization coverage was defined as 
the percentage of vaccinated individuals among the 
resident population of the target group and was cal-
culated for the age group initially involved in the 
vaccination campaign (11-45 years). The vaccination 
coverage was not calculated for the age group of over 
45 years because the period of analysis included less 
than a month after the recommendation to extend the 
vaccination offer to older age groups. In fact, during 
the campaign, the meningococcal C vaccination was 
even extended to the entire population in particular 
areas of the region. A filled out consent form was col-
lected from all the vaccines and for those aged more 
than 55 years additional information were provided: 
they were informed that no studies were available on 
the efficacy of the vaccine for people aged over 55 
years.
Adverse reactions following vaccine administration 
were collected and monitored using the adverse drug 
reaction (ADR) reporting system. ADR records re-
garding subjects not involved in the target population 
of the emergency campaign were excluded. 
Results
Regional deliberations and working group
To face the increasing incidence of IMD cases start-
ing from 2015 in Tuscany, one dose of meningococ-
cal ACWY quadrivalent vaccine was offered free of 
charge to adolescents (11-18 years, including previ-
ously vaccinated subjects). Subsequently, the offer 
was extended to people aged 18-20 and 21-45 living 
in the LHUs, where at least one case of meningococ-
cal C disease had occurred [11, 12]. Due to the high 
occurrence of cases among people aged over 45 years, 
in February 2016, the meningococcal vaccination was 
extended to all people aged over  11 years free of 
charge in the LHUs where meningococcal cases have 
been reported. Particularly, the meningococcal quad-
rivalent ACWY vaccine was offered to people aged 
between 11 and 20 years and the monovalent menin-
gococcal  C vaccine to people aged over 20 years 
(Fig. 1) [13].
For citizens aged over 45 years living in the other 
areas of Tuscany, the meningococcal vaccines were 
available on the basis of co-payment, with a reduced 
ticket [13].
To reach the objectives established by the regional 
health authorities, a multidisciplinary working group 
was constituted in the LHU of Florence to plan and 
organize the emergency campaign. In particular, the 
following professionals were involved: the Health Di-
rectorate of the LHU, the Hygiene and Public Health 
Service Operative Unit (OU), the Responsibles of the 
Health Service Booking Centre, and the Health Care 
Assistance OU. 
Planning of the campaign: identification  
of target population, vaccination settings 
and healthcare professionals involved
The first step was to quantify the target population of 
the vaccination programme and the available places 
for administering the vaccine, both in a hospital set-
ting and in the public health districts. 
At the beginning of the campaign, the target popu-
lation of the vaccination programme consisted of 
310,410 people aged between 11 and 45 years in the 
LHU of Florence. After the extension of the vaccina-
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tion offer to people aged over 45 years, the number 
increased to 743,128. 
The vaccine was administered at 19 vaccination sites: 
five in hospitals and 14 in health districts over an area 
of 2,779 km2. 
Healthcare professionals working in the public health 
services administered the vaccines. Each vaccination 
centre was assigned to a responsible physician, and 
one or more healthcare assistants were simultaneous-
ly involved in the administration of vaccinations.
To guarantee the vaccination offer, additional employ-
ees – doctors, nurses, and healthcare assistants – were 
hired during the monitoring period. Based on shared 
guidelines, people with a history of allergy or ana-
phylactic reactions were referred to the Allergy and 
Clinical Immunology Unit in a hospital care setting, 
where personnel with expertise in the management of 
allergic conditions could guarantee additional safety 
measures.
Moreover, to improve the administration of vaccines, 
the LHU Health Directorate entered into an agree-
ment with General Practitioners (GPs) and Primary 
Care Paediatricians. Each physician involved in the 
campaign had to confirm his/her participation on a 
voluntary basis via email to a dedicated address. The 
list of the paediatricians and GPs participating in the 
vaccination campaign was available on the LHU web-
site. The LHU operators provided the list of unvacci-
nated patients of the primary target age group (11-20 
years) to each GP or paediatrician to increase the im-
munization coverage of their patients.
As far as primary care was concerned, 88 among 
109  primary care paediatricians (80.7%) and 412 
among 606 GPs (68%) participated in the emergency 
vaccination programme. 
Moreover, an agreement was established with some 
voluntary associations to organize vaccination clinics 
for the volunteers themselves and it was subsequently 
extended to all citizens.
In addition, the LHU involved their occupational phy-
sicians to provide meningococcal C vaccine doses to 
private companies interested in getting their workers 
vaccinated.
Communication activities
The communication campaign with the population 
included different strategies to improve population’s 
adherence.
Firstly, a dedicated toll-free telephone number, man-
aged by healthcare assistants, was activated to offer 
information regarding the vaccination programme. If 
the line was busy, people could leave a voice message 
with their name and telephone number, to be called 
later by a healthcare assistant.
During the whole immunization campaign, several 
press releases –  in newspapers and on the radio, tel-
evision, and websites  –  were issued at the regional 
and local levels [14, 15].
Letters containing information regarding the disease 
and the vaccination campaign were sent to mayors, 
to secondary schools, local education agencies, and 
sports associations.
Moreover, vaccine promotion days for voluntary as-
sociations were also organized. In particular, the vac-
cine days were promoted with the support of the Ital-
ian Red Cross.
Since October 2015, about 8,000 informative SMSs 
were sent to people aged between 18 and 20 years who 
had previously accessed the Booking Centre number. 
The SMS text was as follows: “LHU of Florence re-
minds free meningococcal C vaccination for citizens 
aged 11-45 years”. In the same period, an informative 
voice message on the meningococcal C campaign was 
Fig. 1. The meningococcal C vaccination programme in Tuscany from 2005 to February 2016.
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relayed during the waiting time before speaking to the 
operator at the LHU Booking Centre.
Reminders for vaccination appointments were sent 
via SMS the week before the scheduled date.
Public health and primary care services also played 
an important role in the communication strategy. They 
informed people about the disease, its prevention 
through vaccination, and the way to access immuni-
zation services (Fig. 2).
Monitoring of vaccination demand, coverage 
and ADR
The working group for the evaluation of the vaccine 
campaign monitored the vaccination demand continu-
ously, on a daily basis. The weekly average trend of 
vaccination demand from April 22, 2015 to February 
29, 2016 and the day of the onset of the IMD symp-
toms have been shown in Figure 3.
Following the first IMD cases, the weekly demand 
for vaccination increased twofold from the first to 
the second week of monitoring. The values increased 
from 538 to over 1,000 weekly contacts. 
During summer, the average weekly demand for vac-
cination reached its lowest level.
The highest values were recorded in February 2016. 
In week 45, 3,280 daily contacts were registered on an 
average, with more than 4,000 requests being received 
on workdays and a peak of 5,334 contacts.
During the monitoring period, the demand for vacci-
nation was zero or very low on weekends or national 
holidays. Only in the last month of the observation 
period, even during the weekends, an average of more 
than 400 contacts was registered. 
Public health service professionals recorded vaccina-
tions in a computerized immunization register or in 
paper forms, while the GPs and Primary Care Pae-
diatricians emailed periodic reports to the LHU staff.
During the evaluation period (April 2015 - February 
2016) 64,998 subjects aged between 11 and 45 years 
(32,053 in the 11-20 age group and 32,945 in the 21-
45 age group) were vaccinated, reaching the cover-
age of 21%. The vaccination coverage obtained in the 
LHU of Florence and in Tuscany has been reported in 
Table I.
In the LHU of Florence, 20 adverse reactions in the 
target population were notified to the reporting sys-
tem in that period. Among the about 65,000 admin-
istered doses, 18 mild reactions (fever, swelling, red-
ness and pain at the injection site, general feeling of 
discomfort, and headache) were reported. Only two 
severe reactions, both with complete recovery, were 
reported to the monitoring system. One case was of 
convulsion and bradycardia and another of hyperpy-
rexia and delirium.
The ADR reporting rate in the overall period was 
3.1/10,000. The mean age of the people with an ad-
verse reaction was 28 years (range: 11-43 years).
Discussion
The regional emergency meningococcal  C vaccina-
tion campaign was planned and implemented in an 
extremely short time. Moreover, it was continuously 
adjusted to the evolution of the epidemiological situ-
ation. 
The main goal of the vaccination programme was to 
protect adolescents and young adults – the most sus-
ceptible subgroups of the population – and to reduce 
the bacterial circulation among the general popula-
tion, by means of the herd immunity effect, through 
the vaccination of people aged 11-20 years with a sin-
gle dose of meningococcal ACWY vaccine. 
The achievement of high coverage rates among ado-
lescents is an important public health issue, in order 
to reduce the nasopharyngeal carriage [16]. Converse-
ly, the vaccination offer to older people mostly repre-
sents an individual preventive measure.
In 2015, the incidence of meningococcal disease of 
serogroup C in Tuscany was 0.83/100,000, about 
three times higher than the previous years. The me-
dian age of the cases was 28 years (range 3-82). Most 
of the cases occurred in people aged 15-20 and 21-
30 years, with incidence rates of 3.23/100,000 and 
2.83/100,000 respectively [17]. 
Usually, in the previous years, the highest incidence of 
IMD was observed in the younger age groups [7, 16]. 
In Tuscany, a consistent number of cases (28%) has 
occurred in people older than 50 years since 2015. Of 
that, 19% has occurred in people aged over 65 years. 
The increase in the number of IMD cases among 
adults in Tuscany can be partly explained by the ex-
tension of the bio-molecular diagnostic method to 
adults since 2015 [18].
As expected, the occurrence of each new meningo-
coccal invasive case generated a rise in vaccination 
demand. In particular, in February 2016, weekly con-
tacts on workdays were almost 3,000 on an average, 
reaching peaks of over 4,000 requests per day. 
Fig. 2. The LHU of Florence vaccination programme. Organization 
and communication strategies during the emergency meningo-
coccal C campaign in Tuscany.
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The doses supply and vaccination demand were 
checked daily so as to modulate the offer. The vac-
cine doses availability was monitored to ensure an 
adequate response to the vaccination demand for the 
following days. To meet the increased demand for 
vaccines, the doses were also obtained from abroad 
and, starting from February 2016, it was decided that 
the monovalent C vaccine would be used as an alter-
native to the tetravalent vaccine for people aged over 
20 years.
The VC calculated is the most effective measure of 
the population’s adherence to the emergency vaccina-
tion campaign. Concerning the period investigated in 
this study, after 11 months of emergency campaign in 
the LHU of Florence, as well as in Tuscany, around 
21% vaccination coverage was achieved among 11- to 
45-year-old people, while almost half of the primary 
target (subjects aged 11-20) in Tuscany were vacci-
nated in the observation period. This VC was obtained 
thanks to interventions targeting adolescents through 
school-based communication activities, involvement 
of sports associations and SMS with informative text 
on the vaccination campaign sent to subjects aged 18-
20 years. 
Similar emergency meningococcal C vaccination pro-
grams have also been planned in the last decades in 
other Italian regions, such as Veneto, as well as in oth-
er EU countries, due to the changes in IMD incidence 
rates [19-21]. 
In 2007, a cluster of IMD cases, due to the same 
clonal complex ST-11, was reported among subjects 
aged between 15 and 33 years in Veneto. A campaign 
was started to offer meningococcal C vaccination to 
all inhabitants aged between 15 and 29 years living 
in the province of Treviso where the cases occurred. 
The overall vaccination coverage was 60%, but it de-
creased to 40% in the older age group [20, 21].
In England and Wales, the meningococcal vaccina-
tion campaign consisted of a vaccination offer to all 
newborns and citizens aged between five months and 
17 years. GPs administered the vaccine to children 
up to five years, while the subjects belonging to the 
6-17-year-old age group were vaccinated in schools. 
The overall coverage achieved through the school-
based campaign was at least 85%. The highest vac-
cination coverage was reached among children aged 
between 8 and 12 years, while it was the lowest (43%) 
among 15- to 17-year-olds. Adolescents represent a 
difficult group to reach for vaccination and the re-
sults obtained in Tuscany are similar to those in the 
UK [22]. 
Nevertheless, IMD cases continued to occur in Tus-
cany and some cases were also registered among the 
vaccinated subjects. The occurrence of IMD in the 
vaccinated subjects has been reported in other EU 
countries, too  [23]. However, in Tuscany, the fatal 
cases in 2015 occurred only in the subjects who were 
never vaccinated or who were vaccinated many years 
before. Following this evidence and in accordance 
with confirmation from scientific literature, Tuscany 
region recommended meningococcal vaccination for 
all adolescents, included the subjects already vacci-
nated in childhood  [24,  25]. Currently, in Tuscany, 
meningococcal C vaccination consists of a three-dose 
Tab. I. The meningococcal C vaccination coverage for people aged 
11-20 and 21-45 years in the Local Health Unit of Florence and in 
Tuscany (April 2015 - February 2016).
Age 
group
Vaccination coverage 
in LHU of Florence
Vaccination coverage 
in Tuscany 
11-20 ya 47.1% 46.3%
21-45 yb 13.6% 14.1%
Total 20.9% 21.2%
a: LHU of Florence inhabitants - 68,082; Tuscany inhabitants - 317,911; b: 
LHU of Florence inhabitants - 242,328; Tuscany inhabitants - 1,119,990.
Fig. 3. The average weekly demand for meningococcal vaccination and the date of invasive meningococcal casesa (a: the date of the onset 
of symptoms in the cases have been reported in the boxes) in Tuscany (April 22, 2015 - February 29, 2016).
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schedule: the first dose at 13-15 months (monovalent 
vaccine), the second dose at six to nine years (mono-
valent vaccine), and the third dose at 13-20 years 
(quadrivalent ACWY vaccine). This strategy is sup-
ported by the evidence that meningococcal serogroup 
C antibody levels wane rapidly after meningococcal 
conjugate vaccination among young children, leav-
ing adolescents with low antibody levels. Booster 
doses are needed to sustain antibody levels in teens. 
Moreover, in Tuscany, the second (or the third) dose 
with meningococcal ACWY vaccine is guaranteed to 
subjects aged between nine and 20 years already vac-
cinated more than five years previously. During the 
transition to the new vaccination schedule with three 
doses, vaccination is also assured for unvaccinated 
subjects aged up to 20 years [26]. 
Our results described about a year of emergency cam-
paign in the LHU of Florence and the population’s 
adherence to the vaccination offer. When this report 
was being written, the emergency meningococcal  C 
vaccination campaign in Tuscany was still going on 
and the number of primary care physicians involved 
in the vaccination campaign had increased [27]. 
In 2017, only 10 IMD cases were reported, suggesting 
the effectiveness of the meningococcal immunization 
campaign among adolescents and the general popula-
tion [28]. The achievement of greater vaccination cov-
erage is restricted by a sentiment of hesitancy towards 
vaccines among the general population, especially as 
far as the safety issues of vaccinations are concerned. 
However, the ADR reporting rate on meningococcal 
vaccine for our study confirms the safety of the menin-
gococcal vaccination, even for adolescents and adults.
Conclusions
IMD cases in Tuscany sparked alarm among the gen-
eral population and prompted the health authorities 
to plan an emergency vaccination and communica-
tion program. The preventive activities provided by 
the LHU of Florence, in agreement with the regional 
health authorities, represented an example of good 
practice in the surveillance and control of this par-
ticularly frightening disease. 
Moreover, the involvement of public health profes-
sionals and primary care physicians made possible the 
widest distribution of vaccinations in the Florentine 
area, even to the subjects who were the most difficult 
to reach, such as adolescents and young adults, with 
satisfactory adherence to the vaccination campaign.
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